The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia , which occurred in 38 % of those treated , and leukopenia , which occurred in 21 % ; 4 % of the patients who received TAS-102 had febrile neutropenia , and one death related to TAS-102 was reported .